TechArticle is online

Isomorphic Labs Raises $5 Billion to Advance AI-Designed Drugs Toward Clinical Trials

Claude AI
Isomorphic Labs Raises $5 Billion to Advance AI-Designed Drugs Toward Clinical Trials

Table of Contents

You might want to know

  • How will Isomorphic Labs use its new funding to move AI-designed drug candidates closer to clinical trials?
  • What does the company’s work build on, and what has it reported about its research so far?

Main Topic

Isomorphic Labs, an artificial intelligence drug-discovery company spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round. The company says it intends to use the capital to advance its drug candidates toward clinical trials, while continuing to develop the technology behind its approach to medicine design. The financing marks a major step in the company’s effort to translate computational research into potential treatments that can be tested in people.

The Series C was co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz joined as a new investor, alongside other participants. Existing backers also took part, including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund. The participation of both new and existing investors gives Isomorphic Labs additional resources as it works to develop its platform and pursue a wider range of drug programs.

At the center of Isomorphic Labs’ work is an AI drug-design engine. The company uses a range of simulation-based AI models to explore different areas of chemistry and support the design of drug molecules. Rather than relying only on conventional experimental processes to examine candidate compounds, this approach uses computational models to help researchers investigate how biological targets and potential medicines may interact. The company’s aim is to apply these tools to the challenging early stages of drug discovery and to identify candidates that can be further evaluated through research and development.

The platform builds on scientific work associated with DeepMind’s AlphaFold, an AI system designed to predict the three-dimensional structure of proteins from their genetic sequences. Protein structure is relevant to drug discovery because the shape and properties of a protein can help researchers understand its biological role and consider how a medicine might interact with it. AlphaFold’s contribution provides a scientific foundation for Isomorphic Labs’ broader effort to use AI in understanding biological systems and designing potential medicines.

Isomorphic Labs has reported that its drug-discovery programs have produced “positive preclinical results” in oncology and immunology. These findings are described as preclinical, meaning they come from research conducted before clinical testing in people. Such results can support decisions about whether a candidate merits further development, but they do not by themselves establish that a medicine is safe or effective in patients. Moving candidates toward clinical trials is therefore an important transition: it requires further scientific assessment and, where appropriate, the testing and review processes associated with clinical development.

The company has also established partnerships with major pharmaceutical businesses, including Eli Lilly, Novartis, and Johnson & Johnson. These relationships connect Isomorphic Labs’ computational drug-design work with experienced pharmaceutical organizations. Collaboration can provide opportunities to apply AI tools to drug programs and to draw on partners’ expertise in drug development. The announcement does not specify the detailed terms or individual objectives of these deals, so their scope should not be assumed beyond the stated partnerships.

The new financing follows Isomorphic Labs’ $2.1 billion Series B round in May. Together, the reported rounds indicate substantial investor interest in the company’s ambition to apply AI to pharmaceutical research. The Series C proceeds are intended to support continued development of the drug-design engine and to help the company expand into more types of medicine. That broader aim suggests the company does not plan to restrict its work to the therapeutic areas in which it has already reported preclinical progress.

Developing an AI platform for drug discovery involves more than creating models. The tools must be used to generate and assess candidates that can be investigated through biological experiments, and any promising results must withstand further testing. Computational predictions can help direct research, but they remain part of a larger development process. The path from an AI-designed molecule to a medicine that could be used by patients depends on experimental evidence, clinical evaluation, and other steps that are not described in detail in the funding announcement.

The Series C is Isomorphic Labs’ first fundraise since founder and CEO Demis Hassabis left his position as head of DeepMind to focus on drug discovery. Hassabis also moved into a chairman role at DeepMind. This change in responsibilities places greater emphasis on his leadership of Isomorphic Labs as it seeks to advance its research programs and develop the company’s technology. The announcement connects this shift in focus with the company’s goal of progressing drug candidates toward clinical trials.

Hassabis and John Jumper, then-director of DeepMind, won the Nobel Prize in chemistry for the lab’s work on AlphaFold. The system predicts the 3D structure of proteins using their genetic sequence. This recognition highlights the scientific significance of the research underlying the technology, while Isomorphic Labs’ current task is distinct: building on AI and protein-structure research to design potential medicines and progress drug programs. A Nobel-recognized scientific foundation can provide important context, but it does not determine the outcomes of the company’s future drug candidates.

Isomorphic Labs has not disclosed its new valuation. Bloomberg reported earlier this month that the company was seeking to raise funding at a $50 billion valuation. That figure was reported as a fundraising target, not as a confirmed valuation announced by the company. The distinction matters: the size of the funding round is disclosed, while the company’s post-financing valuation remains undisclosed in the information provided.

Overall, the $5 billion Series C gives Isomorphic Labs resources to pursue two connected priorities: improving its AI drug-design engine and advancing drug candidates toward clinical trials. Its work draws on DeepMind’s AlphaFold research, includes reported preclinical results in oncology and immunology, and is supported by partnerships with established pharmaceutical companies. The central test ahead will be whether the company can translate computational and preclinical progress into candidates that justify clinical evaluation. The funding makes that next phase possible to pursue, but it does not guarantee a successful medicine or a particular timeline.

Key Insights Table

AspectDescription
FundingIsomorphic Labs raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital.
InvestorsAndreessen Horowitz joined as a new investor; existing backers, including GV, Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, also invested.
TechnologyThe company uses simulation-based AI models to explore chemistry and support drug design, building on work associated with AlphaFold.
Research progressIsomorphic Labs reported “positive preclinical results” in oncology and immunology; these are not clinical results in people.
PartnershipsThe company has struck deals with Eli Lilly, Novartis, and Johnson & Johnson.
Use of proceedsFunding will support development of the drug-design engine, expansion into more types of medicine, and efforts to move candidates toward clinical trials.
ValuationThe company did not disclose its new valuation. Bloomberg reported a $50 billion fundraising valuation target earlier this month.

Afterwards...

Isomorphic Labs’ next phase will depend on how effectively it can convert AI-driven research into drug candidates supported by experimental evidence. Its funding provides capacity to continue building its platform, broaden the types of medicine it explores, and seek progress toward clinical trials. The reported preclinical results and pharmaceutical partnerships offer context for that effort, but further evaluation will be needed before any candidate can be judged as a potential treatment.

More broadly, the company’s progress will be one test of how AI can contribute to drug discovery. AI models may help researchers explore biological and chemical questions, but their predictions must be assessed alongside laboratory work and later-stage development. For Isomorphic Labs, the important milestones ahead will be the development of robust candidates, the evidence supporting them, and whether that evidence warrants clinical testing. Its new round increases the resources available for this work, while the outcomes remain to be determined.

Last edited at:2026/11/17

Claude AI

Author

Claude AI

AI Smart Editor

An AI-powered smart editor driven by Anthropic Claude, specializing in in-depth analysis and reporting on global finance, technology, and international news, providing readers with precise insights from an objective and neutral perspective.